Karyopharm Therapeutics Inc. SEC filings KPTI
Karyopharm Therapeutics Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Apr 2, 2015. Its latest annual report, Form ARS, was filed on Apr 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | May 27, 2026 | — |
| S-8 | Employee stock plan registration | May 27, 2026 | — |
| S-3 | Shelf registration | May 4, 2026 | — |
| S-3 | Shelf registration | May 4, 2026 | — |
| 424B3 | Prospectus | Nov 24, 2025 | — |
| 424B3 | Prospectus | Nov 24, 2025 | — |
| S-3 | Shelf registration | Nov 3, 2025 | — |
| S-3 | Shelf registration | Nov 3, 2025 | — |
| S-8 | Employee stock plan registration | Aug 11, 2025 | — |
| S-8 | Employee stock plan registration | Nov 5, 2024 | — |
| S-3 | Shelf registration | May 30, 2024 | — |
| S-8 | Employee stock plan registration | May 30, 2024 | — |
| S-8 | Employee stock plan registration | Aug 2, 2023 | — |
| S-3 | Shelf registration | Feb 17, 2023 | — |
| S-8 | Employee stock plan registration | Feb 17, 2023 | — |
| S-3 | Shelf registration | Dec 23, 2022 | — |
| S-8 | Employee stock plan registration | Jun 3, 2022 | — |
| S-8 | Employee stock plan registration | Feb 28, 2022 | — |
| S-8 | Employee stock plan registration | Aug 5, 2021 | — |
| S-3ASR | Automatic shelf registration | Aug 5, 2021 | — |
| S-8 | Employee stock plan registration | Feb 24, 2021 | — |
| S-8 | Employee stock plan registration | Aug 4, 2020 | — |
| 424B5 | Prospectus supplement | May 5, 2020 | — |
| S-8 | Employee stock plan registration | Mar 13, 2020 | — |
| 424B5 | Prospectus supplement | Mar 4, 2020 | — |
| 424B5 | Prospectus supplement | Mar 2, 2020 | — |
| S-3ASR | Automatic shelf registration | Feb 26, 2020 | — |
| S-8 | Employee stock plan registration | Aug 7, 2019 | — |
| 424B5 | Prospectus supplement | May 10, 2019 | — |
| S-8 | Employee stock plan registration | Feb 28, 2019 | — |
| POS AM | Filing | Feb 28, 2019 | — |
| 424B5 | Prospectus supplement | Aug 17, 2018 | — |
| S-8 | Employee stock plan registration | Aug 7, 2018 | — |
| S-3ASR | Automatic shelf registration | Jul 2, 2018 | — |
| 424B5 | Prospectus supplement | May 3, 2018 | — |
| 424B5 | Prospectus supplement | May 1, 2018 | — |
| S-8 | Employee stock plan registration | Mar 15, 2018 | — |
| S-3/A | S-3/a amendment no. 1 to form s-3 | Feb 7, 2018 | — |
| S-3 | Shelf registration | Jan 26, 2018 | — |
| 424B5 | Prospectus supplement | Dec 1, 2017 | — |
| 424B5 | Prospectus supplement | Apr 26, 2017 | — |
| 424B5 | Prospectus supplement | Apr 24, 2017 | — |
| S-8 | Employee stock plan registration | Mar 16, 2017 | — |
| S-3 | Shelf registration | Nov 8, 2016 | — |
| 424B5 | Prospectus supplement | Nov 8, 2016 | — |
| 424B5 | Prospectus supplement | May 19, 2016 | — |
| POS AM | Pos am (amendment no. 3) | May 17, 2016 | — |
| S-8 | Employee stock plan registration | Mar 15, 2016 | — |
| POS AM | Post affective amendment no. 2 to form s-3 | Mar 15, 2016 | — |
| 424B5 | Prospectus supplement | Dec 8, 2015 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KPTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newton, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1503802
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.